The injectable obesity medications Semaglutide 2.4 mg, a selective GLP-1 receptor agonist, produces robust and durable weight loss of approximately 1516% over 68 weeks ( Tirzepatide, a dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonist, delivers even greater weight loss, exceeding 20% at the highest dose in pivotal trials ( Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, represents a further step in efficacy, with 24.2% weight loss achieved within 48 weeks in phase 2 studies ( Survodutide, an oxyntomodulin analogue, achieved clinically meaningful weight loss ( Table 2
Researchers concluded that resistance to the peptide is unlikely to arise from long-term treatment and greater weight loss may be shown over time
Qu son los GLP-1 y cmo funcionan
But knowing what night sweats are and why they happen can help you figure out when you need support from your healthcare team
Retatrutide May Be Studied for Other Health Conditions Retatrutide is mainly known for weight-loss research, but scientists are also studying it for other health problems
